Catherine M. Gerard

机构：GlaxoSmithKline (Belgium), GlaxoSmithKline (Switzerland) · ORCID：0000-0002-9915-4477

发表论文 181 篇 · 总被引 8081 次 · h-index 41

代表论文

• Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 70)
• Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene (2022 · Molecular Therapy · 被引 50)
• Medical practice variation: public reporting a first necessary step to spark change (2018 · International Journal for Quality in Health Care · 被引 50)
• Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. (2018 · PubMed · 被引 47)
• Neutrophil-Derived Interleukin 16 in Premetastatic Lungs Promotes Breast Tumor Cell Seeding (2017 · Cancer Growth and Metastasis · 被引 29)
• Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate (2022 · Clinical & Translational Immunology · 被引 28)